Pharma channel feed

$107B in 2+ years? Pfiz­er’s Covid-19 vac­cine may re­de­fine ‘megablock­buster’ by 2022 — an­a­lyst

4 years ago
Coronavirus

FDA ap­proves pricey new treat­ment for ul­tra-rare and ag­gres­sive form of sar­co­ma

4 years ago
FDA+

Eight years and $1.3B lat­er, As­traZeneca fi­nal­ly un­veils Cam­bridge R&D palace

4 years ago

Glax­o­SmithK­line's Trel­e­gy ad change-up spurs bet­ter re­lata­bil­i­ty with COPD pa­tients — and more doc­tor con­ver­sa­tions

4 years ago
Marketing

Name that vac­cine: From Comir­naty to Spike­vax to Nu­vax­ovid, Covid-19 shot­s' brand names re­main lit­tle-known

4 years ago
Marketing

As J&J moves to split its busi­ness, ex­ecs lay out fu­ture R&D fo­cus — and tout megablock­buster po­ten­tial

4 years ago
R&D

In­dus­try gets the edge: Medicare drug price ne­go­ti­a­tions will on­ly cost bio­phar­ma 10 drugs over the next 30 years

4 years ago
Financing

Aca­dia teams with sto­ry­telling gi­ant Sto­ryCorps to record Parkin­son’s sto­ries — and erase stig­ma

4 years ago
Marketing

Ahead of ex­pect­ed EU ob­jec­tions, Il­lu­mi­na de­fends Grail ac­qui­si­tion

4 years ago
Deals

Lis­ten up phar­ma: Au­dio con­tent from stream­ing mu­sic to pod­casts is on the rise — and so are ad op­por­tu­ni­ties

4 years ago
Marketing

Q&A: As sci­ence gets its mo­ment, J&J’s glob­al brand stew­ard Seema Ku­mar aims to am­pli­fy the peo­ple be­hind the dis­cov­er­ies

4 years ago
Marketing

Mar­ket­ingRx roundup: Bris­tol My­ers taps young NBA play­er to raise heart con­di­tion aware­ness; Pfiz­er, J&J top in­no­va­tion list

4 years ago
Marketing

Epizyme rolls out rare blood can­cer ef­fort with pa­tients' sto­ries and friend­ly dig­i­tal coach

4 years ago
Marketing

In quest to elim­i­nate trop­i­cal dis­eases, Mer­ck KGaA will sub­mit an­ti-worm­ing drug for ap­proval in young chil­dren

4 years ago

First in­ter­change­able biosim­i­lar launch­es in the US with a tiny dis­count on list price

4 years ago

ICER finds un­sub­stan­ti­at­ed drug price in­creas­es cost US $1.67B in 2020, but over­all net in­creas­es low­er than years past

4 years ago

Mer­ck ap­plies DIY mind­set to can­cer screen­ings, adding to in­dus­try post-pan­dem­ic ef­forts

4 years ago
Marketing

As Gink­go looks to clear its name, the feds have come sniff­ing around on the heels of short sell re­port

4 years ago

Just the idea of Aduhelm's long-term fi­nan­cial risks has CMS jack­ing up pre­mi­ums, de­ductibles for 2022

4 years ago
FDA+

Glax­o­SmithK­line’s Vi­iV Health­care aims to shift HIV dai­ly pill think­ing in first DTC ads

4 years ago
Marketing

As­traZeneca ex­pects 'mod­est prof­itabil­i­ty' for next round of Covid-19 vac­cine sup­ply deals — and prunes pipeline in Q3 up­date

4 years ago
R&D

Cit­ing mi­graine drug growth and pan­dem­ic, Lund­beck to cut 300 jobs and close In­dia fa­cil­i­ty

4 years ago

In­fer­til­i­ty and alien ba­bies? Klick Health part­ners with YouTube to tack­le most searched Covid vac­cine con­cerns

4 years ago
Marketing

Opin­ion: The drug pric­ing deal is­n't re­al­ly a vic­to­ry for Dems, or a loss for PhRMA. But it could be a har­bin­ger of change

4 years ago
FDA+
First page Previous page 232233234235236237238 Next page Last page
A service from the Financial Times